-
Medical Resources in Canada and OECD countries. »
-
Evidence that innovative medicines improve health and economic outcomes. »
-
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options. »
-
Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018. »
-
Facts about the cost of patented drugs in Canada: 2018 Edition. »
-
VIDEO - National Pharmacare Facts. »
-
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare? »
-
New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making »
-
How much will National Pharmacare cost taxpayers? »
-
Coverage of new medicines in Federal-Provincial public drug plans 2008-2017 »
-
Public plans cover fewer new drugs than private plans: National Pharmacare will reduce access »
-
Is Canada under-investing in the use of medical devices? »
-
Who needs pharmacare? All Canadians are covered under existing private and public drug plans. »
-
Expertise gaps on Canada’s HTA advisory committees »
-
Consequences of over-regulating the prices of new drugs in Canada »
-
Costs without benefits for patients? Non-medical spending in Canada’s public health system »
-
Does Canada need a Patented Medicine Prices Review Board? »
-
The fiscal burden of provincial government health spending across Canada »
-
Abuse deterrent formulations for all prescription opioids could save $billions in societal costs »
-
Hospital spending compared across Canada’s Provinces »
-
HTA and delays to accessing mental health drugs in Canada »
-
Fewer treatment options for patients if Canada adopts New Zealand's prescription drug policies »
-
Governments could save $5 billion annually by allowing modest user charges for physician services »
-
How long do new patented medicines have market exclusivity in Canada’s public drug plans? »
-
What is the cost of physicians across Canada by province? »
-
Economic cost of lost health gains from delayed access to 14 new cancer drugs. »
-
Capturing value for patients: HTA and the utility-expansion of new cancer drugs. »
Latest
-
Medical Resources in Canada and OECD countries. 2019 Edition.
Canada’s health system supplies patients with fewer medical resources than the health systems of most OECD countries. »
-
Evidence that innovative medicines improve health and economic outcomes: focused literature review.
There is abundant empirical evidence that pharmaceutical innovation improves population-level health outcomes and societal-level net economic benefits. »
-
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options.
Study weighs the options being considered by the federal Advisory Council on the Implementation of National Pharmacare. »
-
Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018.
The pCPA should demonstrate to Canadians that its negotiations to contain the costs of new drugs are not limiting patients’ access to innovative drugs. »
-
Facts about the cost of patented drugs in Canada: 2018 Edition.
Policymakers are not fully informed about pharmaceutical costs - particularly regarding patented medicines. »
-
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?
National Pharmacare advocates claim that out-of-pocket costs for prescription drugs are forcing people to trade-off food, heat and rent versus medicines. Is it true? »
-
New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making
This case study demonstrates that the proposed changes in the PMPRB’s guidelines will create a high level of uncertainty among manufacturers of drugs for rare disorders. »
-
Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate
Study suggests PBO underestimated the cost of National Pharmacare; adjusting the gaps in existing public drug plans would be less expensive for taxpayers. »
-
Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017
Public drug plan coverage is low, slow and inconsistent: bad news for patients, Pharmacare and pCPA. »
